Offerings - Offering: 1	Jul. 31, 2026 USD ($) shares
Offering:
Fee Previously Paid	false
Other Rule	true
Security Type	Equity
Security Class Title	Common stock, $0.001 par value per share, 2025 Equity Incentive Plan
Amount Registered \| shares	4,000,000
Proposed Maximum Offering Price per Unit	175.365
Maximum Aggregate Offering Price	$ 701,460,000
Fee Rate	0.01381%
Amount of Registration Fee	$ 96,871.63
Offering Note	(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock of Neurocrine Biosciences, Inc. (the “Registrant”) that become issuable under the Registrant’s 2025 Equity Incentive Plan (the “2025 Plan”) by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock, as applicable. (2) Estimated in accordance with Rule 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of 175.365 per share of common stock, which represents the average of the high and low prices of the Registrant's common stock as reported on The Nasdaq Global Select Market on July 24, 2026. (3) Represents 4,000,000 additional shares of Registrant’s common stock that were added to the shares authorized for issuance under the 2025 Plan on May 27, 2026 pursuant to approval of the stockholders at the 2026 Annual Meeting of Stockholders.

Offerings - Offering: 1

Jul. 31, 2026

USD ($)

Offering:

false

true

Equity

Common stock, $0.001 par value per share, 2025 Equity Incentive Plan

Amount Registered | shares

4,000,000

Proposed Maximum Offering Price per Unit

175.365

Maximum Aggregate Offering Price

$ 701,460,000

Fee Rate

0.01381%

Amount of Registration Fee

$ 96,871.63

Offering Note

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock of Neurocrine Biosciences, Inc. (the “Registrant”) that become issuable under the Registrant’s 2025 Equity Incentive Plan (the “2025 Plan”) by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock, as applicable.

(2) Estimated in accordance with Rule 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of 175.365 per share of common stock, which represents the average of the high and low prices of the Registrant's common stock as reported on The Nasdaq Global Select Market on July 24, 2026.

(3) Represents 4,000,000 additional shares of Registrant’s common stock that were added to the shares authorized for issuance under the 2025 Plan on May 27, 2026 pursuant to approval of the stockholders at the 2026 Annual Meeting of Stockholders.